Association of aldosterone synthase gene - 344 T/C polymorphism with early renal damage in Han nationality with essential hypertension

Chinese Journal of Medical Genetics

Volumn 24, Issue 2, 2007, Pages 153-156

  Sun, Xiao Jian ^a   Liu, Shao Rong ^a   Zhang, Chuan Huan ^a   Yuan, Guo Hui ^a   Chen, Hong Ying ^a   Hou, Xiao Fei ^b  

^a QINGDAO UNIVERSITY   (China)

^b YANTAI YUHUANGDING HOSPITAL   (China)

Author keywords

Aldosterone synthase gene; Essential hypertension; Microalbuminuria; Renal damage

Indexed keywords

ALBUMIN; ALDOSTERONE; ALDOSTERONE SYNTHASE;

ADULT; ALBUMIN BLOOD LEVEL; ALBUMINURIA; ARTICLE; CONTROLLED STUDY; ESSENTIAL HYPERTENSION; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; KIDNEY INJURY; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; RADIOIMMUNOASSAY; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ADULT; ALBUMINS; ALBUMINURIA; ALDOSTERONE; ALDOSTERONE SYNTHASE; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; FEMALE; GENOTYPE; HUMANS; HYPERTENSION; KIDNEY DISEASES; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; RADIOIMMUNOASSAY;

EID: 34247232064     PISSN: 10039406     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Haller H, Viberti GC, Mimran A, et al. Preventing microalbuminuria in patients with diabetes: rationale and design of the randomised olmesartan and diabetes microalbuminuria prevention (ROADMAP) study. J Hypertens, 2006, 24:403-408.
2. Burnier M, Zanchi A. Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes. J Hypertens, 2006, 24:11-25.
3. Michel MC, Hahntow I, Koopmans RP. Multiple gene approaches to delineate the role of the renin-angiotensin-aldosterone system in nephropathy. J Hypertens, 2005, 23:269-272.
4. Isaji M, Mune T, Takada N, et al. Correlation between left ventricular mass and urinary sodium excretion in specific genotypes of CYP11B2. J Hypertens, 2005, 23:1149-1157.
5. Tamaki S, Iwai N, Tsujita Y, et al. Genetic polymorphism of CYP11B2 gene and hypertension in Japanese. Hypertension, 1999, 33:266-270.
6. Schrader J, Luders S, Kulschewski A, et al. Microalbuminuria and tubular proteinuria as risk predictors of cardiovascular morbidity and mortality in essential hypertension: final results of a prospective long-term study (MARPLE study). J Hypertens, 2006, 24:541-548.
7. Davies E, Kenyon CJ. CYP11B2 polymorphisms and cardiovascular risk factors. J Hypertens, 2003, 21:1249-1253.
8. Pojoga L, Gautier S, Blanc H, et al. Genetic determination of plasma aldosterone level in essential hypertension. Am J Hypertens, 1998, 11:856-860.
9. Hughes DB, Britton ML. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers for prevention and treatment of nephropathy associated with type 2 diabetes mellitus. Pharmacotherapy, 2005, 25:1602-1620.
10. Wang YY, Zhang QY, Wang PL. The relationship between angiotensin converting enzyme gene polymorphism and hypertensive kidney lesion and PAI-1 in hypertension patients. Hereditas, 2003, 25:641-644.
11. Zhou X, Ono H, Ono Y, et al. Aldosterone antagonism ameliorates proteinuria and nephrosclerosis independent of glomerular dynamics in L-NAME/SHR model. Am J Nephrol, 2004, 24:242-249.